Home By PE Sector Buyout Royalty Pharma says Elan’s ‘incoherent’ strategy could destroy value

Royalty Pharma says Elan’s ‘incoherent’ strategy could destroy value

By

Sergei Balashov

-

May 29, 2013

672

Private equity firm Royalty Pharma warned Elan shareholders that the Irish biotech group’s value could drop below $10

Technology partner